The effect of use simvastatin at treatment of ischemic heart disease patients of senile age
Abstract
Aim. To study influence of simvastatin application on clinic, the laboratory and tool data, and as the remote forecast at patients with ischemic heart disease of senile age (75 years and are more senior) with clinic of chronic heart failure.
Material and methods. . 60 men were included in research and women in the age of from 75 till 85 years, hearts suffering by ischemic illness with display of intimate insufficiency and divided on 2 equal groups a method of random numbers. Ill control group received standard therapy concerning ischemic heart disease and chronic heart failure, and ill groups of research, in addition to standard therapy, received simvastatin in a doze 20 mg / days. The period of supervision - 12 months.
Results. On the termination of the period of supervision there was an authentic divergence of curves survivals in observably groups for the benefit of the patients accepting simvastatin; authentic improvement of function vascular endothelium, reduction of a class of a stenocardia in group of intervention is marked. Clinical results are confirmed with decrease of level СRP, TNFá. Authentic growth of level NO of plasma in group of simvastatin application was not observed, and this fact in the given research contacts additional reception or a cancellation of prolonged nitrates patients during treatment.
Сonclusion. By results of the executed research positive influence simvastatin on clinic and the forecast of outcome of disease at patients of the senile age, suffering is confirmed with ischemic illness of heart. Significant growth of the by-effects limiting application simvastatin in a daily doze of 20 mg at patients to the given age group, is not marked. Research will be continued.
About the Authors
A. L. Pirogov
Chelyabinsk regional clinical therapeutic hospital for veterans of wars
Russian Federation
Russian Federation
S. P. Sinitsyn
The Chelyabinsk state medical academy
Russian Federation
Russian Federation
V. K. Rufanova
Chelyabinsk regional clinical therapeutic hospital for veterans of wars
Russian Federation
Russian Federation
E. M. Ermak
Chelyabinsk regional clinical therapeutic hospital for veterans of wars
Russian Federation
Russian Federation
E. V. Davydova
The Chelyabinsk state medical academy
Russian Federation
Russian Federation
References
1. Koh KK, Son JW, Ahn JY, et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis 2001; 12(4): 305-11.
2. Lefer AM, Campbell B, Shin YK, et al. Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100(2): 178-84.
3. Kozaki K. Management of elderly hypertensive individuals with hyperlipidemia. Nippon Rinsho 2005; 63(6): 1061-6.
4. Остроумова О.Д., Дубинская Р.Э. Старение и дисфункция эндотелия. Кардиоваск тер профил 2004; 4: 83-9.
5. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156(18): 2085-92.
6. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. JACC 1997; 30(5): 1212-7.
7. Alfon J, Pueyo Palazon C, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 1999; 81(5): 822-7.
8. Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103(18): 2248-53.
9. de Divitiis M, Rubba P, Di Somma S, et al. Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol 1996; 78(7): 763-8.
10. Mostaza JM, del Valle Gornez Martinez M, Gallardo F, et al. Increase of myocardial perfusion during antilipemic treatment in patients with ischemic cardiopathy. Rev Esp Cardiol 1996; 49(9): 669-74.
11. Meir ChR, Schlienger RG, Kraeuzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10.
12. Аронов Д.М. Плеотропные эффекты симвастатина. РКЖ 2002; 4: 80-6.
13. Kjekshus J, Pedersen TR, Tobert JA. Lipid-lowering therapy for patients with or at risk of coronary artery disease. Curr Opin Cardiol 1996; 11(4): 418-27.
14. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41(5): 343-70.
15. Емченко Н.Л., Цыганенко О.И., Ковалевская Т.В. Универсальный метод определения нитратов в биосредах организма. Клин лабор диаг 1994; 6: 19-20.
16. Пирогов А.Л., Игнатенко И.В. Хроническая сердечная недостаточность у лиц старшей возрастной группы: особенности течения и факторы, влияющие на выживаемость. Вестник Южно-Уральского гос унив-та 2005; 4(44): 57-60.
17. Васюк Ю.А., Атрощенко Е.С., Ющук Е.Н. Плейотропные эффекты статинов – данные фундаментальных исследований. Сердце 2006; 5(29): 228-37.
Review
For citations:
Pirogov A.L., Sinitsyn S.P., Rufanova V.K., Ermak E.M., Davydova E.V. The effect of use simvastatin at treatment of ischemic heart disease patients of senile age. Cardiovascular Therapy and Prevention. 2007;6(5):5-11. (In Russ.)
Views:
482
Email this article 
